FMP
INmune Bio, Inc.
INMB
NASDAQ
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
9.58 USD
-0.81 (-8.46%)
About
ceo
Dr. Raymond Joseph Tesi M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.inmunebio.com
exchange
NASDAQ
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsb...
CIK
0001711754
ISIN
US45782T1051
CUSIP
45782T105
Address
225 NE Mizner Boulevard
Phone
858 964 3720
Country
US
Employee
11
IPO Date
Feb 4, 2019
Summary
CIK
0001711754
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45782T105
ISIN
US45782T1051
Country
US
Price
9.58
Beta
1.95
Volume Avg.
83.88k
Market Cap
172.69M
Shares
-
52-Week
6.5-14.74
DCF
1.3
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-5.74
P/B
-
Website
https://www.inmunebio.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest INMB News
It looks like there's no news available.
